Clinical Trial Update: Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial updating on the effects of belzutifan on PET tracer uptake (89Zr-DFO-girentuximab) in patients with renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• 89Zr-DFO-girentuximab
• Belzutifan (belzutifan)

Snippet

Sponsor: NYU Langone Health | Conditions: Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Status: RECRUITING